CovidChloroV1, Main, Corpus, bibRecord, 000F98

Systemic immunosuppression in times of COVID-19: Do we need to rethink our standards?

Identifieur interne : 000F98 ( Main/Corpus ); précédent : 000F97; suivant : 000F99

Systemic immunosuppression in times of COVID-19: Do we need to rethink our standards?

Auteurs : Stephan Grabbe ; Stefan Beissert ; Alexander Enk

Source :

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG [ 1610-0387 ] ; 2020.

RBID : pubmed:32743938

English descriptors

KwdEn :
- Antiviral Agents (pharmacology), COVID-19 (drug therapy), COVID-19 (immunology), Chloroquine (pharmacology), Doxycycline (pharmacology), Humans (MeSH), Hydroxychloroquine (pharmacology), Immunosuppression (adverse effects).
MESH :
- chemical , pharmacology : Antiviral Agents, Chloroquine, Doxycycline, Hydroxychloroquine.
- adverse effects : Immunosuppression.
- drug therapy : COVID-19.
- immunology : COVID-19.
- Humans.

Abstract

The current SARS-CoV-2 pandemic particularly endangers older people with pre-existing cardiopulmonary and metabolic conditions. However, it is also currently under discussion whether patients under immunosuppressive therapy also have a higher risk of suffering a severe course of the COVID-19 disease. In principle though, there is currently no data available for a general reduction or pause of immunosuppression in patients with autoimmune diseases because of the SARS-CoV-2 pandemic. However, since there is currently neither an effective therapy nor corresponding vaccination protection, the indication for a prolonged immunosuppressive therapy should be made with special care. In particular, immunotherapeutic agents that produce long-term effects (e.g., rituximab) should be used with special caution. In contrast, immunomodulating substances that do not suppress antiviral immunity (e.g. systemic immunoglobulins, doxycycline), or that have intrinsic effects on SARS-CoV-2 (calcineurin inhibitors, chloroquine, hydroxychloroquine) may be useful alternatives.

DOI: 10.1111/ddg.14194
PubMed: 32743938
PubMed Central: PMC7436367

Links to Exploration step

pubmed:32743938

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Systemic immunosuppression in times of COVID-19: Do we need to rethink our standards?</title>
<author><name sortKey="Grabbe, Stephan" sort="Grabbe, Stephan" uniqKey="Grabbe S" first="Stephan" last="Grabbe">Stephan Grabbe</name>
<affiliation><nlm:affiliation>Department of Dermatology, Johannes Gutenberg University, Mainz, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Beissert, Stefan" sort="Beissert, Stefan" uniqKey="Beissert S" first="Stefan" last="Beissert">Stefan Beissert</name>
<affiliation><nlm:affiliation>Department of Dermatology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Enk, Alexander" sort="Enk, Alexander" uniqKey="Enk A" first="Alexander" last="Enk">Alexander Enk</name>
<affiliation><nlm:affiliation>Department of Dermatology, University Hospital of the Ruprecht-Karls-University, Heidelberg, Germany.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32743938</idno>
<idno type="pmid">32743938</idno>
<idno type="doi">10.1111/ddg.14194</idno>
<idno type="pmc">PMC7436367</idno>
<idno type="wicri:Area/Main/Corpus">000F98</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000F98</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Systemic immunosuppression in times of COVID-19: Do we need to rethink our standards?</title>
<author><name sortKey="Grabbe, Stephan" sort="Grabbe, Stephan" uniqKey="Grabbe S" first="Stephan" last="Grabbe">Stephan Grabbe</name>
<affiliation><nlm:affiliation>Department of Dermatology, Johannes Gutenberg University, Mainz, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Beissert, Stefan" sort="Beissert, Stefan" uniqKey="Beissert S" first="Stefan" last="Beissert">Stefan Beissert</name>
<affiliation><nlm:affiliation>Department of Dermatology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Enk, Alexander" sort="Enk, Alexander" uniqKey="Enk A" first="Alexander" last="Enk">Alexander Enk</name>
<affiliation><nlm:affiliation>Department of Dermatology, University Hospital of the Ruprecht-Karls-University, Heidelberg, Germany.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG</title>
<idno type="eISSN">1610-0387</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (pharmacology)</term>
<term>COVID-19 (drug therapy)</term>
<term>COVID-19 (immunology)</term>
<term>Chloroquine (pharmacology)</term>
<term>Doxycycline (pharmacology)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (pharmacology)</term>
<term>Immunosuppression (adverse effects)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Chloroquine</term>
<term>Doxycycline</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Immunosuppression</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The current SARS-CoV-2 pandemic particularly endangers older people with pre-existing cardiopulmonary and metabolic conditions. However, it is also currently under discussion whether patients under immunosuppressive therapy also have a higher risk of suffering a severe course of the COVID-19 disease. In principle though, there is currently no data available for a general reduction or pause of immunosuppression in patients with autoimmune diseases because of the SARS-CoV-2 pandemic. However, since there is currently neither an effective therapy nor corresponding vaccination protection, the indication for a prolonged immunosuppressive therapy should be made with special care. In particular, immunotherapeutic agents that produce long-term effects (e.g., rituximab) should be used with special caution. In contrast, immunomodulating substances that do not suppress antiviral immunity (e.g. systemic immunoglobulins, doxycycline), or that have intrinsic effects on SARS-CoV-2 (calcineurin inhibitors, chloroquine, hydroxychloroquine) may be useful alternatives.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32743938</PMID>
<DateCompleted><Year>2020</Year>
<Month>12</Month>
<Day>29</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1610-0387</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>18</Volume>
<Issue>8</Issue>
<PubDate><Year>2020</Year>
<Month>08</Month>
</PubDate>
</JournalIssue>
<Title>Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG</Title>
<ISOAbbreviation>J Dtsch Dermatol Ges</ISOAbbreviation>
</Journal>
<ArticleTitle>Systemic immunosuppression in times of COVID-19: Do we need to rethink our standards?</ArticleTitle>
<Pagination><MedlinePgn>810-813</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/ddg.14194</ELocationID>
<Abstract><AbstractText>The current SARS-CoV-2 pandemic particularly endangers older people with pre-existing cardiopulmonary and metabolic conditions. However, it is also currently under discussion whether patients under immunosuppressive therapy also have a higher risk of suffering a severe course of the COVID-19 disease. In principle though, there is currently no data available for a general reduction or pause of immunosuppression in patients with autoimmune diseases because of the SARS-CoV-2 pandemic. However, since there is currently neither an effective therapy nor corresponding vaccination protection, the indication for a prolonged immunosuppressive therapy should be made with special care. In particular, immunotherapeutic agents that produce long-term effects (e.g., rituximab) should be used with special caution. In contrast, immunomodulating substances that do not suppress antiviral immunity (e.g. systemic immunoglobulins, doxycycline), or that have intrinsic effects on SARS-CoV-2 (calcineurin inhibitors, chloroquine, hydroxychloroquine) may be useful alternatives.</AbstractText>
<CopyrightInformation>© 2020 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grabbe</LastName>
<ForeName>Stephan</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Dermatology, Johannes Gutenberg University, Mainz, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Beissert</LastName>
<ForeName>Stefan</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Dermatology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Enk</LastName>
<ForeName>Alexander</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Dermatology, University Hospital of the Ruprecht-Karls-University, Heidelberg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>08</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Germany</Country>
<MedlineTA>J Dtsch Dermatol Ges</MedlineTA>
<NlmUniqueID>101164708</NlmUniqueID>
<ISSNLinking>1610-0379</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>N12000U13O</RegistryNumber>
<NameOfSubstance UI="D004318">Doxycycline</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004318" MajorTopicYN="N">Doxycycline</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007165" MajorTopicYN="N">Immunosuppression</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>05</Month>
<Day>18</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>06</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>8</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>12</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>8</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32743938</ArticleId>
<ArticleId IdType="doi">10.1111/ddg.14194</ArticleId>
<ArticleId IdType="pmc">PMC7436367</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Virol. 2012 Sep;86(17):9274-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22718826</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 May 14;369:m1849</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32409561</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Dermatol. 2020 Aug;183(2):373-374</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32343839</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e295-e297</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32302437</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2021 Jan;80(1):e10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32312768</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Kidney Int. 2020 Jun;97(6):1083-1088</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32354634</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2020 Aug;26(8):1839-1841</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32384045</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Transplant. 2020 Oct;20(10):2958-2959</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32368838</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunotherapy. 2020 Jun;12(8):571-576</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32397847</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Mol Sci. 2020 May 10;21(9):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32397684</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Dtsch Dermatol Ges. 2017 Feb;15(2):228-241</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28036140</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2010 Mar 19;140(6):805-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20303872</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Kidney Int. 2020 Jun;97(6):1076-1082</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32354637</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Eur Acad Dermatol Venereol. 2020 Nov;34(11):e676-e679</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32564417</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Autoimmun. 2020 Aug;112:102473</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32439209</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Open Forum Infect Dis. 2020 Apr 29;7(5):ofaa153</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32455147</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Cardiol. 2020 May 13;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32402056</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Thromb Haemost. 2020 Aug;18(8):2075-2076</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32470213</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Endocrinol Invest. 2020 Aug;43(8):1141-1147</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32335855</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2020 Oct;79(10):1382-1383</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32398281</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2017 May;76(5):891-897</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27903507</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Netw Open. 2020 Apr 24;3(4):e208857</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32330277</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ecancermedicalscience. 2020 Mar 27;14:1022</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32256705</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2020 Jun;79(6):837-839</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32332072</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nefrologia. 2020 May - Jun;40(3):272-278</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32389518</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Immunol. 2020 May 01;11:827</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32425950</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cochrane Database Syst Rev. 2019 Feb 24;2:CD010406</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30798570</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jul 2;383(1):85-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32348641</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Dermatol. 2019 Feb;58(2):172-177</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30350359</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 2020 Jun 1;217(6):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32353870</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jul 17;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32678530</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Mol Immunol. 2020 Jun;17(6):650-652</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32346099</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Allergy Clin Immunol Pract. 2020 Sep;8(8):2575-2581.e2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32565226</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Med (Lausanne). 2020 Apr 24;7:170</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32391369</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F98 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000F98 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:32743938
   |texte=   Systemic immunosuppression in times of COVID-19: Do we need to rethink our standards?
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:32743938" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Systemic immunosuppression in times of COVID-19: Do we need to rethink our standards?

Systemic immunosuppression in times of COVID-19: Do we need to rethink our standards?

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki